TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis

This competitive intelligence report about TL1A Inhibitors and DR3 Antagonists provides a competitor evaluation in the field of mostly antibodies targeting TNF-like ligand 1A (TL1A) or death receptor 3 (DR3) as of July of 2025.

TL1A as a target for mainly inflammatory bowel disease recently has received great interest from major pharmaceutical companies as evidenced by numerous business development activities including acquisitions and in-licensing triggering significant payments.

The superfamily of tumor necrosis factors (TNF) and the TNF-receptor (TNFR) contain many molecules with vital functions in an array of signaling pathways. One of the most important functions include their role in the development and regulation of the immune system. A member of this family, TNF-like cytokine 1A (TL1A), which is encoded by the TNFSF15 gene, is a transmembrane protein that can be found in both membrane-bound or soluble forms. While both of these forms are structurally similar, they have unique effects on immunological function.

TL1A signals by binding to its receptor, death domain receptor 3 (DR3 or TNFFRSFf25). DR3 shares the most significant homology to TNFR1 among all the TNFR proteins in the superfamily. Downstream signaling following TL1A and DR3 binding include mucosal immunity, intestinal homeostasis, and development and maintenance of inflammatory responses, which can greatly affect patients with diseases such as inflammatory bowel disease (IBD).

In addition to monospecific inhibitors of TL1A or antagonists of its receptor, an increasing number of bispecific and even trispecific antibodies targeting TL1A/DR3 are in development. The second (and third) target include p40, interleukin-23 (IL-23) (p19), NLRP3, and alpha4beta7 (α4β7). At least 13 distinct TL1A-targeting molecules are in clinical development and more are in the non-clinical development and preclinical R&D pipeline.

This product consists of a competitor description and analysis in a tabular format provided as a pdf document which is sent by e-mail within one day, usually within one hour.

The pdf report includes a compilation of currently active projects in research and development of TL1A- or DR3-targeted product candidates.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis reports:
Competitor Analysis reports deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced with hyperlinks to the source of information.